VERTEX PHARMACEUTICALS INC / MA Insider Trading for October 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in VERTEX PHARMACEUTICALS INC / MA.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in VERTEX PHARMACEUTICALS INC / MA for October 2017.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Sell | S | 149.34 | 200 | 29,868 | 40,888 | 41.1 K to 40.9 K (-0.49 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Sell | S | 148.26 | 3,791 | 562,054 | 41,088 | 44.9 K to 41.1 K (-8.45 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Sell | S | 147.40 | 3,500 | 515,900 | 44,879 | 48.4 K to 44.9 K (-7.23 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Sell | S | 146.39 | 5,200 | 761,228 | 48,379 | 53.6 K to 48.4 K (-9.71 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Sell | S | 145.26 | 22,464 | 3,263,121 | 53,579 | 76 K to 53.6 K (-29.54 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Sell | S | 144.47 | 32,945 | 4,759,564 | 76,043 | 109 K to 76 K (-30.23 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Sell | S | 143.47 | 5,200 | 746,044 | 108,988 | 114.2 K to 109 K (-4.55 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Sell | S | 142.40 | 1,700 | 242,080 | 114,188 | 115.9 K to 114.2 K (-1.47 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 96.87 | 2,125 | 205,849 | 6,375 | |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 149.34 | 500 | 74,670 | 41,952 | 42.5 K to 42 K (-1.18 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 148.54 | 1,000 | 148,540 | 42,452 | 43.5 K to 42.5 K (-2.30 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 147.87 | 5,000 | 739,350 | 43,452 | 48.5 K to 43.5 K (-10.32 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 146.61 | 7,783 | 1,141,066 | 48,452 | 56.2 K to 48.5 K (-13.84 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 145.34 | 17,501 | 2,543,595 | 56,235 | 73.7 K to 56.2 K (-23.73 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 144.54 | 25,999 | 3,757,895 | 73,736 | 99.7 K to 73.7 K (-26.07 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 143.54 | 5,600 | 803,824 | 99,735 | 105.3 K to 99.7 K (-5.32 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 142.18 | 11,617 | 1,651,705 | 105,335 | 117 K to 105.3 K (-9.93 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 149.00 | 2,125 | 316,625 | 116,952 | 119.1 K to 117 K (-1.78 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 96.87 | 2,125 | 205,849 | 119,077 | 117 K to 119.1 K (+1.82 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 141.41 | 4,165 | 588,973 | 116,952 | 121.1 K to 117 K (-3.44 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 149.34 | 200 | 29,868 | 54,424 | 54.6 K to 54.4 K (-0.37 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 148.40 | 1,400 | 207,760 | 54,624 | 56 K to 54.6 K (-2.50 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 147.75 | 3,400 | 502,350 | 56,024 | 59.4 K to 56 K (-5.72 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 146.52 | 4,700 | 688,644 | 59,424 | 64.1 K to 59.4 K (-7.33 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 145.26 | 19,016 | 2,762,264 | 64,124 | 83.1 K to 64.1 K (-22.87 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 144.46 | 25,784 | 3,724,757 | 83,140 | 108.9 K to 83.1 K (-23.67 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 143.46 | 4,100 | 588,186 | 108,924 | 113 K to 108.9 K (-3.63 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 142.38 | 1,400 | 199,332 | 113,024 | 114.4 K to 113 K (-1.22 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 149.34 | 100 | 14,934 | 50,710 | 50.8 K to 50.7 K (-0.20 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 148.35 | 1,000 | 148,350 | 50,810 | 51.8 K to 50.8 K (-1.93 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 147.70 | 2,200 | 324,940 | 51,810 | 54 K to 51.8 K (-4.07 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 146.53 | 3,200 | 468,896 | 54,010 | 57.2 K to 54 K (-5.59 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 145.26 | 12,438 | 1,806,744 | 57,210 | 69.6 K to 57.2 K (-17.86 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 144.47 | 17,362 | 2,508,288 | 69,648 | 87 K to 69.6 K (-19.95 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 143.49 | 2,800 | 401,772 | 87,010 | 89.8 K to 87 K (-3.12 %) |
Oct 31 2017 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 142.40 | 900 | 128,160 | 89,810 | 90.7 K to 89.8 K (-0.99 %) |
Oct 18 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Option Exercise | M | 96.87 | 2,125 | 205,849 | 6,375 | |
Oct 18 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Sell | S | 157.07 | 200 | 31,414 | 115,888 | 116.1 K to 115.9 K (-0.17 %) |
Oct 18 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Sell | S | 156.24 | 850 | 132,804 | 116,088 | 116.9 K to 116.1 K (-0.73 %) |
Oct 18 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Sell | S | 155.03 | 875 | 135,651 | 116,938 | 117.8 K to 116.9 K (-0.74 %) |
Oct 18 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Sell | S | 154.01 | 200 | 30,802 | 117,813 | 118 K to 117.8 K (-0.17 %) |
Oct 18 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Buy | M | 96.87 | 2,125 | 205,849 | 118,013 | 115.9 K to 118 K (+1.83 %) |
Oct 18 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Option Exercise | M | 96.87 | 1,718 | 166,423 | 5,157 | |
Oct 18 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 157.38 | 300 | 47,214 | 114,424 | 114.7 K to 114.4 K (-0.26 %) |
Oct 18 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 155.92 | 300 | 46,776 | 114,724 | 115 K to 114.7 K (-0.26 %) |
Oct 18 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 154.76 | 818 | 126,594 | 115,024 | 115.8 K to 115 K (-0.71 %) |
Oct 18 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 153.42 | 300 | 46,026 | 115,842 | 116.1 K to 115.8 K (-0.26 %) |
Oct 18 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Buy | M | 96.87 | 1,718 | 166,423 | 116,142 | 114.4 K to 116.1 K (+1.50 %) |
Oct 18 2017 | VRTX | VERTEX PHARMACEUTI ... | SACHS BRUCE I | Director | Option Exercise | A | 0.00 | 265 | 0 | 5,858 | |
Oct 16 2017 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Option Exercise | M | 90.29 | 2,125 | 191,866 | 23,375 | |
Oct 16 2017 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Sell | S | 152.93 | 2,125 | 324,976 | 28,809 | 30.9 K to 28.8 K (-6.87 %) |
Oct 16 2017 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Buy | M | 90.29 | 2,125 | 191,866 | 30,934 | 28.8 K to 30.9 K (+7.38 %) |
Oct 04 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Option Exercise | M | 73.51 | 3,437 | 252,654 | 3,438 | |
Oct 04 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 152.62 | 600 | 91,572 | 114,424 | 115 K to 114.4 K (-0.52 %) |
Oct 04 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 151.82 | 1,443 | 219,076 | 115,024 | 116.5 K to 115 K (-1.24 %) |
Oct 04 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 151.04 | 1,394 | 210,550 | 116,467 | 117.9 K to 116.5 K (-1.18 %) |
Oct 04 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Buy | M | 73.51 | 3,437 | 252,654 | 117,861 | 114.4 K to 117.9 K (+3.00 %) |